As of June 6, 2025, Evogene Ltd has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $394.30, this represents a potential upside of -2104504.4%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -171440.7% |
| Potential Upside (10-year) | -2104504.4% |
| Discount Rate (WACC) | 5.5% - 7.8% |
Revenue is projected to grow from $1 million in 12-2020 to $733 million by 12-2030, representing a compound annual growth rate of approximately 93.4%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2020 | 1 | 38% |
| 12-2021 | 2 | 133% |
| 12-2022 | 6 | 131% |
| 12-2023 | 13 | 123% |
| 12-2024 | 26 | 107% |
| 12-2025 | 51 | 95% |
| 12-2026 | 95 | 88% |
| 12-2027 | 170 | 78% |
| 12-2028 | 287 | 69% |
| 12-2029 | 469 | 63% |
| 12-2030 | 733 | 56% |
Net profit margin is expected to improve from -2520% in 12-2020 to -2499% by 12-2030, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2020 | (26) | -2520% |
| 12-2021 | (61) | -2511% |
| 12-2022 | (141) | -2508% |
| 12-2023 | (314) | -2506% |
| 12-2024 | (648) | -2503% |
| 12-2025 | (1,265) | -2501% |
| 12-2026 | (2,380) | -2501% |
| 12-2027 | (4,247) | -2500% |
| 12-2028 | (7,179) | -2500% |
| 12-2029 | (11,712) | -2499% |
| 12-2030 | (18,322) | -2499% |
with a 5-year average of $1 million. Projected CapEx is expected to maintain at approximately 47% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2021 | 1 |
| 12-2022 | 1 |
| 12-2023 | 2 |
| 12-2024 | 5 |
| 12-2025 | 9 |
| 12-2026 | 18 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 49 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2021 | (57) | (0) | 1 | 0 | (58) |
| 2022 | (132) | (0) | 3 | 1 | (135) |
| 2023 | (295) | (0) | 6 | 1 | (302) |
| 2024 | (610) | (1) | 12 | 2 | (624) |
| 2025 | (1,191) | (2) | 24 | 4 | (1,217) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -171440.7% |
| 10-Year DCF (Growth) | 0.00 | -2104504.4% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Evogene Ltd (EVGN.TA) a buy or a sell? Evogene Ltd is definitely a sell. Based on our DCF analysis, Evogene Ltd (EVGN.TA) appears to be overvalued with upside potential of -2104504.4%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $394.30.